Literature DB >> 25284599

Effectiveness of a two-stage strategy with HPV testing followed by visual inspection with acetic acid for cervical cancer screening in a low-income setting.

Pierre-Marie Tebeu1, Joël Fokom-Domgue, Victoria Crofts, Emmanuel Flahaut, Rosa Catarino, Sarah Untiet, Pierre Vassilakos, Patrick Petignat.   

Abstract

The World Health Organization recently advocated a two-stage strategy with human papillomavirus (HPV) testing followed by visual inspection of the cervix with acetic acid (VIA) as a suitable option for cervical cancer screening. However, its accuracy has never been directly assessed in the context of primary screening. To evaluate effectiveness of HPV testing on self-obtained specimens (self-HPV) followed by VIA (sequential testing) in a low-income setting, we recruited 540 women aged between 30 and 65 years in two Cameroonian periurban areas. Eligible women were counseled about cervical cancer and how to perform self-sampling. HPV positive and a random sample of HPV-negative women were called back for VIA and biopsy. Disease was defined by interpretation of cervical intraepithelial neoplasia Grade 2 or worse (CIN2+). Performances of VIA, self-HPV and sequential testing were determined after adjustment for verification bias. HPV prevalence was 27.0%. VIA positivity was 12.9% and disease prevalence was 5%. Sensitivity and specificity of VIA for CIN2+ were 36.4% [95% confidence interval (CI): 15.2-64.6%] and 90.4% (95% CI: 85.4-93.7%), respectively. Sensitivity of self-HPV [100.0% (95% CI: 79.6-100.0%)] was 66% higher than that of sequential testing [33.3% (95% CI: 15.2-58.3%)]. Meanwhile, specificity of self-HPV [74.5% (95% CI: 70.6-78.1%)] was 22% lower than that of sequential testing [96.7% (95% CI: 94.8-97.9%)]. A two-stage screening strategy with self-HPV followed by VIA improves specificity of cervical cancer screening, but at the cost of an important loss of sensitivity. Ways to improve VIA performance or other tools are needed to increase positive predictive value of HPV testing.
© 2014 UICC.

Entities:  

Keywords:  HPV testing; VIA; accuracy; cervical cancer screening; low-income setting; sequential testing; two-stage strategy

Mesh:

Substances:

Year:  2014        PMID: 25284599     DOI: 10.1002/ijc.29250

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  25 in total

1.  Cervical human papillomavirus DNA detection in women living with HIV and HIV-uninfected women living in Limbe, Cameroon.

Authors:  Adebola Adedimeji; Rogers Ajeh; Anastase Dzudie; Ernestine Kendowo; Norbert Fuhngwa; Denis Nsame; Andre Gaetan Simo-Wambo; Enow Orock; Tiffany M Hebert; Amanda J Pierz; Daniel Murokora; Kathryn Anastos; Philip E Castle
Journal:  J Clin Virol       Date:  2020-05-19       Impact factor: 3.168

2.  Clinical Performance of Human Papillomavirus Testing and Visual Inspection With Acetic Acid in Primary, Combination, and Sequential Cervical Cancer Screening in China.

Authors:  Margaret Z Wang; Rui-Mei Feng; Shaoming Wang; Xian-Zhi Duan; Dong Li; Xun Zhang; Rong Mu; Youlin Qiao; Jennifer S Smith
Journal:  Sex Transm Dis       Date:  2019-08       Impact factor: 2.830

3.  Role of Magnetic Resonance Imaging in Prostate Cancer Screening: A Pilot Study Within the Göteborg Randomised Screening Trial.

Authors:  Anna Grenabo Bergdahl; Ulrica Wilderäng; Gunnar Aus; Sigrid Carlsson; Jan-Erik Damber; Maria Frånlund; Kjell Geterud; Ali Khatami; Andreas Socratous; Johan Stranne; Mikael Hellström; Jonas Hugosson
Journal:  Eur Urol       Date:  2015-12-24       Impact factor: 20.096

4.  Prevalence and risk factors for High-Risk Human Papillomavirus (hrHPV) infection among HIV-infected and Uninfected Rwandan women: implications for hrHPV-based screening in Rwanda.

Authors:  Jean d'Amour Sinayobye; Marc Sklar; Donald R Hoover; Qiuhu Shi; Jean Claude Dusingize; Mardge Cohen; Eugene Mutimura; Brenda Asiimwe-Kateera; Philip E Castle; Howard Strickler; Kathryn Anastos
Journal:  Infect Agent Cancer       Date:  2014-12-08       Impact factor: 2.965

5.  Cost-effectiveness of HPV-based cervical cancer screening in the public health system in Nicaragua.

Authors:  Nicole G Campos; Mercy Mvundura; Jose Jeronimo; Francesca Holme; Elisabeth Vodicka; Jane J Kim
Journal:  BMJ Open       Date:  2017-06-15       Impact factor: 2.692

6.  Cervical cancer screening in a low-resource setting: a pilot study on an HPV-based screen-and-treat approach.

Authors:  Margot Kunckler; Fanny Schumacher; Bruno Kenfack; Rosa Catarino; Manuela Viviano; Eveline Tincho; Pierre-Marie Tebeu; Liliane Temogne; Pierre Vassilakos; Patrick Petignat
Journal:  Cancer Med       Date:  2017-06-04       Impact factor: 4.452

7.  Evidence-based policy choices for efficient and equitable cervical cancer screening programs in low-resource settings.

Authors:  Nicole G Campos; Vivien Tsu; Jose Jeronimo; Mercy Mvundura; Jane J Kim
Journal:  Cancer Med       Date:  2017-07-14       Impact factor: 4.452

8. 

Authors: 
Journal:  J Virus Erad       Date:  2017-10-23

9.  Real-world effectiveness of primary screening with high-risk human papillomavirus testing in the cervical cancer screening programme in China: a nationwide, population-based study.

Authors:  Yanxia Zhao; Heling Bao; Lan Ma; Bo Song; Jiangli Di; Linhong Wang; Yanqiu Gao; Wenhui Ren; Shi Wang; Hai-Jun Wang; Jiuling Wu
Journal:  BMC Med       Date:  2021-07-15       Impact factor: 8.775

10.  Prevalence, Predictors, and Same Day Treatment of Positive VIA Enhanced by Digital Cervicography and Histopathology Results in a Cervical Cancer Prevention Program in Cameroon.

Authors:  Geneva A DeGregorio; Leslie S Bradford; Simon Manga; Pius M Tih; Richard Wamai; Rebecca Ogembo; Zacharie Sando; Yuxin Liu; Constance Schwaiger; Sowmya R Rao; Karen Kalmakis; Lisa Kennedy Sheldon; Kathleen Nulah; Edith Welty; Thomas Welty; Javier Gordon Ogembo
Journal:  PLoS One       Date:  2016-06-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.